03Nov 2024
Denifanstat Shows Promise in Treating MASH with Fibrosis

Denifanstat Shows Promise in Treating MASH with Fibrosis

This phase 2b trial assessed the efficacy and safety of denifanstat, a fatty acid synthase inhibitor, in treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis. Among 168 participants, denifanstat significantly improved liver histology and MASH resolution compared to placebo, with manageable side effects. The findings support further development of denifanstat in phase 3 trials as a potential therapeutic option for MASH-related liver fibrosis.

  • #gastroenterology

Like

Save

Share